.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Johnson and Johnson
Queensland Health
Medtronic
US Department of Justice
Express Scripts
Argus Health
Accenture
Colorcon
McKinsey

Generated: February 23, 2018

DrugPatentWatch Database Preview

Patents Expiring in December 2026

« Back to Dashboard

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Janssen TherapSIRTURObedaquiline fumarateTABLET;ORAL204384-001Dec 28, 2012RXYesYes➤ Sign Up➤ Sign UpYYTREATMENT OF PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS
Perrigo Pharma IntlCLINDESSEclindamycin phosphateCREAM;VAGINAL050793-001Nov 30, 2004RXYesYes➤ Sign Up➤ Sign UpYMETHOD OF TREATING BACTERIAL VAGINOSIS
TevaAZILECTrasagiline mesylateTABLET;ORAL021641-002May 16, 2006ABRXYesYes➤ Sign Up➤ Sign UpY
TevaAZILECTrasagiline mesylateTABLET;ORAL021641-001May 16, 2006ABRXYesNo➤ Sign Up➤ Sign UpY
Wyeth Pharms IncPROTONIXpantoprazole sodiumFOR SUSPENSION, DELAYED RELEASE;ORAL022020-001Nov 14, 2007RXYesYes➤ Sign Up➤ Sign UpY
Vernalis R And D LtdMOXATAGamoxicillinTABLET, EXTENDED RELEASE;ORAL050813-001Jan 23, 2008RXYesYes➤ Sign Up➤ Sign UpY
Vernalis R And D LtdMOXATAGamoxicillinTABLET, EXTENDED RELEASE;ORAL050813-001Jan 23, 2008RXYesYes➤ Sign Up➤ Sign UpYYMETHOD OF TREATING TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES IN A ONCE-A-DAY AMOXICILLIN PRODUCT
Incyte CorpJAKAFIruxolitinib phosphateTABLET;ORAL202192-005Nov 16, 2011RXYesYes➤ Sign Up➤ Sign UpY
Incyte CorpJAKAFIruxolitinib phosphateTABLET;ORAL202192-005Nov 16, 2011RXYesYes➤ Sign Up➤ Sign UpUSE OF RUXOLITINIB (JAKAFI) FOR INHIBITING JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2.
Incyte CorpJAKAFIruxolitinib phosphateTABLET;ORAL202192-005Nov 16, 2011RXYesYes➤ Sign Up➤ Sign UpUSE OF RUXOLITINIB (JAKAFI) FOR BLOCKING SIGNAL TRANSDUCTION OF JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2
This preview shows a limited number of results
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
Covington
Chubb
Deloitte
Cipla
QuintilesIMS
Healthtrust
Dow
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2018 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot